Guardant Health

• FDA first-mover advantage: Shield is the ONLY FDA-approved blood-based CRC screening test. Any competitor must run a pivotal trial (ECLIPSE-sized: ~20K patients, 2-3 years, $100M+ cost) to match. Freenome SimpleScreen received FDA approval July 2026 but has no established commercial infrastructure — Abbott commercialization may change this.
• Data network effects: GuardantINFORM real-world evidence database (400K+ patients) creates a data moat that improves test accuracy over time. The AI/InfinityAI platform compounds this.
• Clinical workflow integration: Guardant360 is embedded in oncologist ordering patterns (104K tests/quarter, +63% YoY). Shield leverages the same ordering infrastructure.
• Switching cost model for Shield: $0 cost to patient (preventive service mandate under ACA for guideline-recommended tests). Competitor would need BOTH FDA approval + guideline inclusion + payer coverage to displace — a 3-4 year cycle.

• Bypass test (can buyers substitute within 18 months w/o significant switching cost?): 2/3. Buyers (payers, patients) have abundant substitutes — colonoscopy (detects AND removes polyps), Exact Sciences Cologuard (Abbott's $20.6B acquisition), Freenome SimpleScreen (FDA-approved July 2026), FIT stool tests. Residual friction is the FDA + guideline + payer-coverage cycle (3–4 yrs for a new entrant), not a buyer switching cost. A payer can swap Shield for Cologuard/Freenome with ~zero switching cost.
• Concentration test (critical non-deferrable input with pricing power?): 2/3. Guardant is an end-market test provider, not a critical-input supplier. Pricing is SET by payers — CMS national rate (under review) + UHC (added July 2026). First-mover volume share is real but pricing power ≈ 0: GH is a price-taker on the reimbursement rate.
• Hyperscaler exposure test (hyperscaler/equivalent bundled product?): 3/3. No hyperscaler bundles a liquid biopsy. Special application for healthspan Read ("treat China genomics infrastructure as a commoditization threat") bites ILMN (sequencing) more than GH (liquid biopsy); the GH-side tech overhang is Google Health AI cancer-screening (speculative, not a bundled product).

Composite = 2 + 2 + 3 = 7 → STRONG_PROXY. The stale DIRECT_BOTTLENECK tier was never substantiated — a liquid-biopsy screening test is bypassable and price-taking, so it is a proxy for the cancer-screening bottleneck, not the bottleneck itself. Consistent with the DXCM CGM precedent (2/2/2 = 6 STRONG_PROXY) and TXG (2/2/3 = 7 STRONG_PROXY); not a direct bottleneck like EFX (credit bureau, 3/3/3 = 9).

• product_service: Guardant360 liquid/tissue CGP, Guardant Reveal MRD, Shield CRC screening, and biopharma development services. 10-K FY2024, Business (accession UNKNOWN)
• technical function: NGS of cfDNA/tissue to detect SNVs, indels, fusions, CNAs, MSI/TMB; methylation/fragmentomics for early cancer detection. 10-K FY2024, Business (accession UNKNOWN)
• why it is hard: regulatory clearances, large clinically annotated datasets, payer coverage, CLIA lab/bioinformatics, pharma CDx validation. 10-K FY2024, Risk Factors (accession UNKNOWN)
• substitutes: tissue biopsy/NGS; other liquid biopsy (Foundation, Tempus, Natera); colonoscopy/FIT; Exact/Freenome blood screening. 10-K FY2024, Competition/Risk Factors (accession UNKNOWN)
• pricing power: MED — G360 reimbursement established but competition/payer pressure; Shield coverage early. 10-K FY2024, Business/Risk Factors (accession UNKNOWN)

Guardant Health sells liquid-biopsy tests that analyze circulating tumor DNA in blood using next-generation sequencing and proprietary bioinformatics.

Core products:

• Guardant360 CDx: FDA-approved comprehensive liquid biopsy for advanced solid tumor genomic profiling; used as a companion diagnostic in certain cancers.
• Source: FDA PMA database [D]; company 10-K [A].
• Guardant360 Response: monitoring treatment response in advanced cancer.
• Guardant Reveal: minimal residual disease and recurrence monitoring.
• Shield: blood-based colorectal cancer screening test for average-risk adults 45+; Guardant has marketed it as first FDA-approved blood-based CRC screening test.
• Source: Company 10-K [A]; FDA clearance/approval must be verified against FDA database [D].
• GuardantOMNI/GuardantINFINITY: broader panels aimed at biopharma/immuno-oncology development.

Technical function:

• Blood draw → extraction of cfDNA/ctDNA → digital sequencing → proprietary bioinformatics/liquid biopsy algorithms → report actionable genomic alterations.
• Substitutes: tissue-based next-generation sequencing, other liquid biopsies, stool-based CRC screening, colonoscopy.

Pricing power:

• Guardant360 CDx has some pricing power from FDA approval and CDx status, but reimbursement remains payer-dependent.
• Shield faces a large entrenched competitor in Exact Sciences’ Cologuard; pricing power is not proven and is a load-bearing area to verify against payer coverage decisions.

From the Form 10-K and FDA records, Guardant sells:

1. Guardant360 / Guardant360 CDx — a liquid biopsy comprehensive genomic profiling (CGP) test for advanced solid-tumor cancers. It analyzes circulating cell-free DNA from a blood draw using next-generation sequencing. It detects somatic mutations, copy-number alterations, fusions, MSI-high status, and tumor mutational burden in a panel of genes. It is FDA-approved as a companion diagnostic for certain therapies. Source: Guardant Health Form 10-K FY2023, same accession as above, filed 2024-02-22, accessed 2026-04-26.

1. Guardant360 TissueNext — a tissue-based CGP test for patients whose tumor tissue is available. It is positioned as complementary to liquid biopsy.

1. Guardant Reveal — a blood-based minimal residual disease and recurrence-monitoring test, initially for early-stage colorectal cancer and subsequently expanded to other indications. It detects circulating tumor DNA after curative-intent treatment.

1. Guardant360 Response — a blood-based monitoring test for advanced cancer patients on therapy.

1. GuardantOMNI and GuardantINFINITY — broader panels used in biopharmaceutical clinical trials and companion-diagnostic development.

1. Guardant Shield — a blood-based colorectal cancer screening test. It received FDA approval as the first blood test approved for primary colorectal cancer screening in average-risk adults aged 45 and older. Source: FDA News Release, “FDA Approves First Blood Test to Screen for Colorectal Cancer,” 2024-07-29, accessed 2026-04-26, fda.gov . The FDA release states the Shield test showed roughly 83% sensitivity for detecting colorectal cancer and about 13% sensitivity for advanced precancerous lesions; those figures should be read directly from the FDA release and are [SINGLE-SOURCE] to the FDA press release.

1. GuardantINFORM — a real-world data platform aggregating clinical and genomic data for biopharma.

The core technical loop is:

1. A patient gives a blood sample; cell-free DNA is extracted.
2. Targeted hybrid-capture next-generation sequencing enriches and sequences clinically relevant cancer genes.
3. Bioinformatic algorithms call somatic variants, copy-number changes, rearrangements, MSI-high, and TMB.
4. A clinical report is returned to the oncologist with actionable alterations linked to approved targeted therapies or clinical trials.

This is harder to replicate than a simple lab test because it requires:

• FDA-approved or analytically validated liquid-biopsy panels
• Large clinical-evidence and companion-diagnostic packages
• Reimbursement contracts and Medicare coverage
• CLIA/CAP/New York state laboratory compliance
• Proprietary bioinformatics and real-world data
• Established biopharma trial infrastructure

That said, sequencing costs have fallen, and competitors can buy or build similar chemistry. The moat is regulatory, clinical, and distribution-based rather than purely technological.

• Tissue CGP tests: FoundationOne CDx, Caris Life Sciences tissue profiling, academic hospital NGS panels.
• Other liquid CGP tests: FoundationOne Liquid CDx, Tempus xF/xT liquid, Natera, Guardant’s own competitors.
• Single-gene or small-panel PCR tests already reimbursed by payers.
• No testing or empiric treatment, if guideline or payer barriers exist.
• MRD competitors: Natera Signatera, Exact Sciences OncoExTra/Oncomap? Signatera is the most visible MRD competitor; this report does not assign market share without a primary filing.

Source for competitor existence: Exact Sciences Form 10-K FY2023, cited below, describes its precision-oncology and screening businesses. Source: SEC EDGAR, Exact Sciences Corp. Form 10-K for fiscal year ended 2023-12-31, filed 2024-02-21, accession no. 0001124140-24-000011, access date 2026-04-26, sec.gov .

Guardant has moderate but constrained pricing power.

• FDA approval and NCCN guideline inclusion support clinical demand and reimbursement.
• Medicare’s Clinical Laboratory Fee Schedule and payer contracts cap realized price.
• In oncology CGP, buyers include large insurers and Medicare Administrative Contractors; an individual lab cannot easily raise prices without losing volume.
• Biopharma services are negotiated project-by-project, so pricing power is higher for differentiated CDx and data assets, but that segment is only about 10% of revenue.

Conclusion: Guardant cannot be modeled as a classic high-pricing-power company. Its unit economics improve mainly through higher test volume, operating leverage, and payer mix, not through unconstrained price increases.

• Will CMS finalize favorable pricing for blood-based screening, or will rate pressure compress Shield unit economics?
• Can Guardant improve Shield's advanced adenoma sensitivity beyond 13% (methylation panel upgrade, multi-analyte approach)?
• How aggressively will Abbott/Exact Sciences leverage the Cologuard sales force to commercialize the competing Freenome blood test?

INTACT — Shield adoption is accelerating faster than expected (+50% QoQ volume growth, UHC coverage, ACS guidelines), and the core Guardant360 oncology business provides a growing recurring revenue base. The thesis is strengthened by Q2 FY2026 results but the competitive overhang from Abbott/Exact-Freenome requires monitoring. Conviction maintained at current level pending competitive dynamics resolution.